QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
| Revenue (TTM) | $2.10B |
| Gross Profit (TTM) | $1.39B |
| EBITDA | $727.68M |
| Operating Margin | 23.80% |
| Return on Equity | 11.90% |
| Return on Assets | 6.01% |
| Revenue/Share (TTM) | $10.18 |
| Book Value | $16.15 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 3.73 |
| EV/Revenue | 4.324 |
| EV/EBITDA | 13.06 |
| Quarterly Earnings Growth (YoY) | -23.80% |
| Quarterly Revenue Growth (YoY) | 1.80% |
| Shares Outstanding | $206.25M |
| Float | $204.78M |
| % Insiders | 0.47% |
| % Institutions | 82.24% |
Volatility is currently expanding
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN).
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s.
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
